A three-decade monopoly: How Amgen built a patent thicket around its top-selling drug
Bio Pharma Dive
OCTOBER 31, 2021
Through high-stakes litigation, aggressive patenting practices and a bit of luck, Amgen will likely stretch Enbrel's monopoly until 2029, more than 30 years after it was approved.
Let's personalize your content